Additional file 1: of Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway

Figure S1. Ivermectin increased the sensitivity of the cells to mitomycin C and adriamycin. Figure S2. The anticancer effects of ivermectin in a leukemia mice model. Figure S3. Ivermectin increases the sensitivity of the cells to vincristine by inhibiting P-gp expression. Figure S4. Ivermectin decreased P-gp expression by inhibiting the ERK/Akt activation. Figure S5. Ivermectin inhibits P-gp expression through EGFR/ERK/Akt/NF-κB pathway. Figure S6. IVM increased the sensitivity of HCT-8 cells to VCR by inhibiting the activation of NF-κB. Figure S7. Ivermectin inhibited the activation of EGFR/ERK/Akt/NF-κB and P-gp expression in K562 cells and HCT-8 xenografts in nude mice. Figure S8. The reversal effects of ivermectin had no related to Wnt/β-catenin and mTOR pathway. (PDF 1407 kb)